BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31056651)

  • 1. G-estimation of structural nested mean models for competing risks data using pseudo-observations.
    Tanaka S; Brookhart MA; Fine JP
    Biostatistics; 2020 Oct; 21(4):860-875. PubMed ID: 31056651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-estimation of structural nested mean models for interval-censored data using pseudo-observations.
    Tanaka S; Brookhart MA; Fine J
    Stat Med; 2023 Sep; 42(21):3877-3891. PubMed ID: 37402505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
    Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
    Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
    Geskus RB
    Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causal inference in survival analysis using pseudo-observations.
    Andersen PK; Syriopoulou E; Parner ET
    Stat Med; 2017 Jul; 36(17):2669-2681. PubMed ID: 28384840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. causalCmprsk: An R package for nonparametric and Cox-based estimation of average treatment effects in competing risks data.
    Vakulenko-Lagun B; Magdamo C; Charpignon ML; Zheng B; Albers MW; Das S
    Comput Methods Programs Biomed; 2023 Dec; 242():107819. PubMed ID: 37774426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causal inference for recurrent event data using pseudo-observations.
    Su CL; Platt RW; Plante JF
    Biostatistics; 2022 Jan; 23(1):189-206. PubMed ID: 32432686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive subdistribution hazards regression for competing risks data in case-cohort studies.
    Wogu AF; Li H; Zhao S; Nichols HB; Cai J
    Biometrics; 2023 Dec; 79(4):3010-3022. PubMed ID: 36606409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Fine-Gray Model Under Interval Censored Competing Risks Data.
    Li C
    J Multivar Anal; 2016 Jan; 143():327-344. PubMed ID: 26543275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented and doubly robust G-estimation of causal effects under a Structural nested failure time model.
    Mertens K; Vansteelandt S
    Biometrics; 2018 Jun; 74(2):472-480. PubMed ID: 28742252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of statistical methods to predict the residual lifetime risk.
    Conner SC; Beiser A; Benjamin EJ; LaValley MP; Larson MG; Trinquart L
    Eur J Epidemiol; 2022 Feb; 37(2):173-194. PubMed ID: 34978669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doubly-robust estimator of the difference in restricted mean times lost with competing risks data.
    Lin J; Trinquart L
    Stat Methods Med Res; 2022 Oct; 31(10):1881-1903. PubMed ID: 35607287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation and modeling of the restricted mean time lost in the presence of competing risks.
    Conner SC; Trinquart L
    Stat Med; 2021 Apr; 40(9):2177-2196. PubMed ID: 33567477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
    Stegherr R; Schmoor C; Beyersmann J; Rufibach K; Jehl V; Brückner A; Eisele L; Künzel T; Kupas K; Langer F; Leverkus F; Loos A; Norenberg C; Voss F; Friede T
    Trials; 2021 Jun; 22(1):420. PubMed ID: 34187527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doubly-robust methods for differences in restricted mean lifetimes using pseudo-observations.
    Choi S; Choi T; Lee HY; Han SW; Bandyopadhyay D
    Pharm Stat; 2022 Nov; 21(6):1185-1198. PubMed ID: 35524651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weighted NPMLE for the Subdistribution of a Competing Risk.
    Bellach A; Kosorok MR; Rüschendorf L; Fine JP
    J Am Stat Assoc; 2019; 114(525):259-270. PubMed ID: 31073256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Proportional Hazards Regression Model for the Sub-distribution with Covariates Adjusted Censoring Weight for Competing Risks Data.
    He P; Eriksson F; Scheike TH; Zhang MJ
    Scand Stat Theory Appl; 2016 Mar; 43(1):103-122. PubMed ID: 27034534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data.
    Zhang X; Zhang MJ; Fine J
    Stat Med; 2011 Jul; 30(16):1933-51. PubMed ID: 21557288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varying coefficient subdistribution regression for left-truncated semi-competing risks data.
    Li R; Peng L
    J Multivar Anal; 2014 Oct; 131():65-78. PubMed ID: 25125711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.